Our managing director Vik Bajaj sat down with Maneesh Jain at portfolio company Mirvie for a conversation on the maternal health crisis, and why precision medicine represents the future of pregnancy health. Mirvie aims to predict pregnancy complications before they happen by using RNA messages to reveal the underlying biology of pregnancy health. We welcome your comments on this important conversation! #maternalhealth #pregnancy #precisionmedicine
Foresite Capital’s Post
More Relevant Posts
-
Congratulations to Molly He and the team at Element Biosciences on their oversubscribed series D financing! We are proud to partner with this team as they push forward with disruptive DNA sequencing and multi-omics technologies to reshape our industry.
Element Biosciences nets $277M ahead of new sequencer launch
fiercebiotech.com
-
Congratulations to Martin Babler & the team at Alumis on their IPO last week! Alumis was incubated by Foresite Labs; the company is developing two Tyrosine Kinase 2 inhibitor product candidates for patients living with immune-mediated diseases who need alternatives to existing treatments. It represents years of work from the therapeutics team at Foresite Capital and the incubation team at Labs. Congrats to all!
-
-
So happy to share that Drs. Hyung Chun and Cindy (Xin) Xiong are now partners at Foresite Capital! Their contributions and leadership have been pivotal in shaping our investment strategies in healthcare and life sciences over the years. Since joining us in 2021, Hyung has brought his extensive expertise as a physician-scientist from Yale School of Medicine and serves on the board of multiple Foresite portfolio companies including Latigo Biotherapeutics, Inc.. Cindy joined our team in 2019, and has been a trailblazer in biotech innovation. She serves on the boards of several portfolio companies including ImmPACT Bio and previously Xinthera, Inc. (board observer, acquired by Gilead). As partners, Hyung and Cindy will lead investments in a wide range of therapeutic areas. Read about their new roles at the link below.
Hyung Chun and Cindy Xiong Promoted to Partner at Foresite Capital
businesswire.com
-
This is a wonderful program, and it's a quick application process. Please help us spread the word to any aspiring VCs from underrepresented backgrounds interested in the life sciences track.
🌟 Calling aspiring and early-career VCs from underestimated backgrounds: Don’t forget that Cohort 17 of @VC University starts in September, and we are offering a limited number of full scholarships to qualified applicants. ⏳The deadline to apply is TONIGHT! Aspiring and early-career VCs, don’t miss your chance: https://lnkd.in/eWwj2nk
-
-
Nice write-up on our Fund VI close from the team at Fierce Biotech. Our CEO Jim Tananbaum says this is “one of the best biotech investment environments” of his multi-decade career. Read more at the link below.
Foresite raises $900M to make big bets in 'one of the best biotech investment environments'
fiercebiotech.com
-
With the closing of our sixth fund at $900 million, we're excited to continue supporting pioneering technologies at the intersection of technology and biotech. Fund VI has invested in companies including Alumis, CG Oncology, Latigo Biotherapeutics, Inc., and Xaira Therapeutics. These companies are redefining what's possible in medicine; from novel treatments to cutting-edge technologies, their efforts are paving the way for a healthier future. We're inspired by the visionary entrepreneurs we work with and grateful for the continued support of our investors. Learn more about Fund VI via Michael Bodley for PitchBook.
Foresite Capital’s $900M VC fund bets on AI to aid biotech plays
pitchbook.com
-
Sharing a fun clip on the proper pronunciation of our portfolio company Xaira Therapeutics by one of their scientists.
We have a special guest who joined the Xaira Pronunciation Nation for today's lesson. Say hello to Clifford and his friend, multi-omics scientist and hairbrush mic pro Bianca Ynez Ruiz Smith. Excellent job, Clifford and Bianca! 12/10. We wish everyone a happy long weekend and start of summer. Enjoy the time with your friends and family -- furry or otherwise. And take the time to check out our open roles if you're interested in joining us!
-
Our portfolio company Mirvie was featured on TODAY.com, highlighting their precision medicine approach to identify those at risk for pregnancy complications and avoid situations like what happened to Lindsay. Women's health is an underserved area and one we are proud to support through companies like Mirvie.
Lindsay’s experience is what drives our work at Mirvie. Nobody should have to go through the trauma she endured. In an ideal scenario, Lindsay would have known her risk of preeclampsia months before experiencing symptoms. This would have given her a window to work closely with her care team to put a preventive action plan in place and stay vigilant for signs and symptoms if it did occur. Her story is a heart-wrenching reminder of the urgency of our work because all mothers deserve the healthiest pregnancies possible. Read more about Lindsay’s story and perspectives from Dallas Reed, MD, FACMG, FACOG Reed and Michal Elovitz on what preeclampsia is and how dangerous it can be for pregnant patients and their babies, as well as innovation on the horizon to shift pregnancy health from reactive to proactive at TODAY.com. And thank you to Preeclampsia Foundation for shining a light on stories like Lindsay’s.
Mom, 32, had a life-threatening pregnancy complication. Doctors dismissed the signs for weeks
today.com
-
Welcome to our portfolio, Xaira Therapeutics! Jointly incubated by Arch Venture Partners and Foresite Labs, and led by renowned scientist Marc Tessier-Lavigne, Xaira emerged from stealth today with $1B in committed capital. Read the exclusive story in Endpoints News.
Incubated by ARCH Venture Partners and Foresite Labs, Xaira Therapeutics is on a mission to drive advances in artificial intelligence to learn the language of life and transform how we treat disease. We’re building significant AI research capabilities spanning fundamental computational methods development and their application to biological discovery, the design of drug-like matter, and clinical development. Xaira emerged from stealth today with $1 billion in committed capital led by ARCH Venture Partners and Foresite Capital, with additional investment from F-Prime Capital, New Enterprise Associates (NEA), Sequoia Capital, LUX Speed Capital, Lightspeed, Menlo Ventures, Two Sigma Ventures, SV Angel and others. Xaira is led by renowned scientist Dr. Marc Tessier-Lavigne, former Chief Scientific Officer of Genentech and former President of Rockefeller and Stanford Universities. Its executives include co-founder Hetu K, formerly of Meta and the Institute for Protein Design; Arvind Rajpal, formerly of Genentech; and Don Kirkpatrick, formerly of Interline and Genentech. Xaira was co-founded by Dr. David Baker, Professor of Biochemistry and Director of Institute for Protein Design, University of Washington. Learn more about our launch from Ryan Cross and Andrew Dunn in Endpoints News.
In biggest-ever bet on using AI to design drugs, biotech heavyweights launch Xaira with $1B+ in backing
https://endpts.com
-
We're happy to see our colleague Shoman Kasbekar included in this piece in the Biomarker newsletter covering rising stars in biotech investing and creation, how they got started, and lessons learned. Shoman shares his perspective on how the success of the investment only begins with the investment itself. Read more at the link below.
24 Biotech Investors in '24
biomarker.substack.com
Executive Assistant, Finance & Corporate Affairs
3mo👏